RMAT

AcronymDefinition
RMATRajasthan Management Admission Test (University of Rajasthan; Jaipur, India)
RMATRapid Micro-Agglutination Test (Legionnaires' disease)
RMATRing Me a Taxi (reservation website)
RMATRisk Management Assessment Tool
RMATReliability and Maintainability Assessment Tool
RMATRemote Maintenance Access Terminal
RMATRhino Music Aptitude Test
References in periodicals archive ?
The US FDA confirmed that MiMedx Allogeneic Micronized Dehydrated Human Amnion/Chorion Membrane (micronized dHACM) meets the criteria for RMAT designation for the treatment of OA of the knee.
To receive the RMAT designation, Capricor submitted data from an earlier trial, the HOPE-Duchenne Trial, which reported significant and sustained improvements in skeletal muscle function and cardiac structure in boys and young men in advanced stages of Duchenne muscular dystrophy following a single dose of intracoronary CAP-1002.
This experiment confirmed the first successful use of RMAT in Crohn's treatment by Professor John Hermon-Taylor in London [Mar/Apr 2004 Post].
To receive the RMAT designation, the company submitted data from an earlier trial, the HOPE-Duchenne Trial, which reported significant and sustained improvements in skeletal muscle function and cardiac structure in boys and young men in advanced stages of Duchenne muscular dystrophy following a single dose of intracoronary CAP-1002.
The FDA's grant of RMAT designation for CEVA101 further validates the compelling safety and efficacy data generated to date, and affirms the program's potential to address a serious and life-threatening condition," said Cellvation CEO Frank Taffy.
This RMAT designation allows for multidisciplinary, comprehensive interactions with the FDA to support the efficient development of and potential accelerated approval pathway for Mesoblast's allogeneic MPCs in the treatment of heart failure patients with LVADs.
This RMAT designation allows for multi-disciplinary, comprehensive interactions with the FDA to support the efficient development of and potential accelerated approval pathway for Mesoblast's allogeneic MPCs in the treatment of heart failure patients with LVADs.
The guidance specifies that devices intended for use with a specific RMAT may, together with the RMAT, be considered to comprise a combination product.
The company was also pleased about the RMAT designation and several other recent positive developments at Asterias:
If granted, the RMAT Designation would be expected to facilitate CAP-1002's path to potential registration.
A product may receive an RMAT designation if the drug is: